BioNTech / Pfizer vaccine less effective in preventing coronavirus cases: study – POLITICO

The BioNTech / Pfizer vaccine appears to be less effective in preventing cases of COVID-19 resulting from the Delta coronavirus variant but remains very effective in preventing hospitalization, according to initial data from Israel.

From June 6 to July 2, the vaccine was shown to be 64% effective in preventing cases and 94% in preventing hospitalizations, Israel’s health ministry said Monday, according to Ynet News.

These results are comparable to previous data showing an efficacy rate of around 94% for the prevention of infections. Between May 2 and June 5, the vaccine was 98% effective in preventing hospitalizations for coronavirus infection.

In the time between the two datasets, the country lifted lockdown restrictions along with the arrival of the Delta variant, which is more transmissible.

Data from the UK also indicated that vaccines are less effective in preventing Delta variant infections, but still effective in preventing serious illness.

Meanwhile, Public Health England said on July 2 that data suggests that vaccine effectiveness against symptomatic illnesses from one dose of the vaccines used provides between 55 and 70 percent effectiveness. Data from two doses indicate an effectiveness of about 65 to 90 percent.

This article is part of POLITICSThe premium police service: Pro Health Care. Whether it’s drug pricing, EMA, vaccines, pharmacy and more, our expert journalists keep you up to date on the topics driving the health policy agenda. E-mail [email protected] for a free trial.